Oxford Supplies COVID-19 Vaccine Assistance to Biopharma Corp

The Challenge

A global leader in research-based biopharmaceuticals needed automation and verification engineering services to support a large initiative to double the production capacity of the COVID-19 vaccine. The project, which would typically span three to five years, needed to be completed within one year.

The client was under extreme pressure to carry out the overwhelming request due to a compelling push from the government to address the devastating global situation due to the virus. Additionally, the company’s CEO announced its commitment to double production within the next year to meet the much-needed demand.

The Solution

The corporation selected Oxford due to past performance in similar areas. Nobody had experience with the vaccine, as the virus was new, and up to this point, an mRNA vaccine had not been commercially developed in regions such as the United States. However, we had previously proven ourselves in onboarding resources, project oversight, and validation. Therefore, the client trusted us to provide quality resources quickly.

Oxford committed to working through the holidays, providing seven team leads that covered shifts 24/7. In all, we supplied our client with nearly 50 high-quality automation, verification, and process engineers. They performed troubleshooting and verification testing of a new automated filling line to successfully startup and double production capacity.

The Result

Oxford played a pivotal role in accelerating the corporation’s vaccine production capabilities. Through strategic collaboration, agile problem-solving, and the deployment of specialized expertise, Oxford enabled the client to meet its ambitious goal of delivering effective vaccine solutions within the calendar year. This achievement not only upheld the corporation’s public commitment but also contributed significantly to global health efforts during a critical period.